A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

被引：3

作者：

O'Donnell, Elizabeth K. ^{[1
]}

Mo, Clifton C. ^{[2
]}

Nadeem, Omar ^{[3
]}

Yee, Andrew J. ^{[4
]}

Branagan, Andrew R. ^{[4
]}

Laubach, Jacob ^{[2
]}

Gammon, Marilyn T. ^{[5
]}

Lively, Kathleen J. ^{[5
]}

Packer, Lisette ^{[5
]}

Harrington, Cynthia C. ^{[5
]}

Agyemang, Emerentia ^{[5
]}

Rosenblatt, Jacalyn ^{[6
]}

Horick, Nora K. ^{[1
]}

Richardson, Paul G. ^{[7
]}

Raje, Noopur ^{[8
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[4] Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[6] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA

[7] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[8] Mass Gen Hosp, Canc Ctr, Boston, MA USA

来源：

关键词：

D O I：

10.1182/blood-2022-156328

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7282 / 7283

页数：2